Dr Sameer Rastogi
@samdoc_mamc
Followers
2K
Following
2K
Media
35
Statuses
951
Additional Professor, Sarcoma and GIST Medical Oncology Clinic, AIIMS, New Delhi, Passionate for the treatment of rare diseases like melanomas endocrine tumors
New Delhi, India
Joined February 2018
⏱️ Oncologists: save patients time & reduce infusion center overload - infuse pembro in 10 minutes instead of 30. ⏱️ Safety data now out in @JCOOP_ASCO, IRR low (4%) & similar to 30 min infusion. @Oncoalert @JCO_ASCO
https://t.co/oWlAq5zujn
ascopubs.org
PURPOSERising cancer incidence and staff shortages demand more efficient outpatient oncology workflows. Pembrolizumab is conventionally administered over 30 minutes. This prospective study assessed...
2
18
96
Safety, Feasibility, and Patient Experience of Ten-Minute Pembrolizumab Infusions: A Prospective Cohort Study |@JCO_ASCO
ascopubs.org
PURPOSERising cancer incidence and staff shortages demand more efficient outpatient oncology workflows. Pembrolizumab is conventionally administered over 30 minutes. This prospective study assessed...
0
3
13
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management. https://t.co/Vu3vdJr49B
0
1
2
Glad to share that Mrs Rashi Kapoor and Mr Lakshay Nagpal have attended the scientific conference BEST OF ESMO conference held in mumbai on 13 th and 14 th December held in St Regis, Mumbai. #BestofESMO
0
2
5
Check out the OnDemand program, “Achieving Disease Control in TGCT: Critical Steps For Integrating Evidence-Based Care With CSF1R Inhibitors” CME for learning more about #TGCT! 🔗send them the link to participate: https://t.co/4HR5y6vjrS
@PeerView
lrn.peerview.com
See a new #TGCT activity via @PeerView @WTapMD #CTOS2025 #MedEd
1
6
8
Excellent presentation by @RosenbergerMd #phyllodes expert 🌟importance of standardized path reporting, her amazing work on genomic landscape, adjuvant therapies 👇🏼👇🏼👇🏼#SABCS25 @DukeSurgOnc
1
9
35
A nice summary of immunotherapy for uterine leiomyosarcoma.
pubmed.ncbi.nlm.nih.gov
Uterine leiomyosarcoma is a rare and aggressive malignancy with limited therapeutic options and poor prognostic outcomes. Immune checkpoint inhibitors have transformed oncology; however, their...
0
2
6
Great insights! @samdoc_mamc
Extremely rare intra osseus sarcomas mainly from jaw bones with EWSR1-TFCP2, Series from India. CK, ALK and MYO D1 are positive. Currently classified as subtype of RMS but behave differently! #sarcoma @aiims_newdelhi
https://t.co/OqrBtgJuvx
0
1
3
Extremely rare intra osseus sarcomas mainly from jaw bones with EWSR1-TFCP2, Series from India. CK, ALK and MYO D1 are positive. Currently classified as subtype of RMS but behave differently! #sarcoma @aiims_newdelhi
https://t.co/OqrBtgJuvx
2
3
20
2. Grateful to @ctosociety for the travel award that made it possible. Deep thanks to @samdoc_mamc for the mentorship and support to present our work. @nihanthy @MedGenomeLabs @BahlCharu @OncoDaily @OncoAlert @CTOSarcoma @AIIMS_NEWDELHI @ASCO @JCOGlobalOnc @Oncology_News
0
2
2
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma | @JCO_ASCO
ascopubs.org
PURPOSESTELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3...
0
1
9
.@PMOIndia 🙏🙏 May like to identify points of relevance from this enclosed piece to amend and strengthen #CAQM for long term solutions as well. This piece is in #HindustanTimes Chandigarh edition. And available on website of #HT
24
59
166
How many of our Honble Ministers in the NCR working with or without air purifiers? How many of them are suffering chest congestion, cough,with stuffy or a running nose..? We wish them all good health. But Is it not their sacred duty to protect their people before they protect
184
308
1K
How officials who are working in offices with purifiers, driving in a car with purifier, and living in a house with purifiers know the air quality outside? Also All at official costs? While many are suffering from chest congestion, running noses, sneezing and coughing. And even
144
296
1K
The nation’s air-pollution crisis is not an accident of the present; it is the outcome of decades without true coordination in governance. (And also lack of integrity at critical levels) Responsibilities are distributed across departments, but accountability ultimately rising
202
178
637
Low-dose RT #LDRT is an effective, non-invasive Rx for #osteoarthritis. At Medanta, we’ve started a prospective trial on LDRT for hand OA- Ethics-approved, CTRI-registered (CTRI/2025/11/098220). #LDRT #RT#OA#Medanta
@deepakonco
@sorunshishak
@susovanBanerje
0
1
2
We are excited to announce a new Cells Special Issue titled "Molecular Pathogenesis and Novel Therapeutic Strategies in Chordoma"! We invite researchers, clinicians, and experts in the field to submit abstracts below: 🔗 https://t.co/Upkz9LD2fZ
0
4
3
@samdoc_mamc @RashiKapoor17 @SachinSarcoma @sorunshishak @ApnaLakshay @DTRFoundation @DesmoidI @desmoidcanada Thanks so much and appreciate your great participation in our conference and hope this will be the initiator for more collaboration and partnership to fill the Gap in sarcoma research and education as well as patient care
0
1
1
Felt amazing to give a talk on #desmoid tumor in Ains Shams University International Oncology Conference, Cairo, Egypt. Thanks @mohamed35475330 for the invitation and for the excellent discussion on #desmoid. Challenges are very much same in 🇮🇳India and 🇪🇬Egypt.
1
2
21
@tuttsakhil @samdoc_mamc Congratulations Dr Akhil and Dr Sameer Rastogi.
0
2
4